Literature DB >> 3306235

Interleukin-1 and osteoarthritis.

J P Pujol, G Loyau.   

Abstract

Il-1, a multifunctional monokine, can stimulate both synoviocytes and articular chondrocytes to release neutral proteases and prostaglandin E2. It is also capable of promoting bone resorption. Therefore, this molecule (or family of molecules) is likely to play an important role in the mechanism of articular cartilage destruction that occurs in degenerative arthropathies. The synovial tissue itself can produce Il-1 (Catabolin) in some conditions, such as a slight traumatism, so that the presence of local inflammation is not necessary for "Il-1-cartilage" interaction to occur. Fundamental macromolecules of cartilage (collagens, proteoglycans) exert a stimulatory effect on Il-1 production, either as such or in the form of immune complexes. Some activated complement fractions (C3a and C5a) may also be actively involved. Studies on the mechanisms which regulate Il-1 synthesis and release, as well as investigations on the response of target cells to Il-1, are presently fascinating goals that could lead to new strategies in therapeutic research.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3306235     DOI: 10.1016/0024-3205(87)90196-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  13 in total

1.  Degradation of proteoglycan aggregate by a cartilage metalloproteinase. Evidence for the involvement of stromelysin in the generation of link protein heterogeneity in situ.

Authors:  Q Nguyen; G Murphy; P J Roughley; J S Mort
Journal:  Biochem J       Date:  1989-04-01       Impact factor: 3.857

2.  Effects of antirheumatic drugs on the interleukin-1 alpha induced synthesis and activation of proteinases in articular cartilage explants in culture.

Authors:  C Arsenis; J McDonnell
Journal:  Agents Actions       Date:  1989-06

3.  Modulation of extracellular matrix metabolism in rabbit articular chondrocytes and human rheumatoid synovial cells by the non-steroidal anti-inflammatory drug etodolac. II: Glycosaminoglycan synthesis.

Authors:  F Redini; A Mauviel; G Loyau; J P Pujol
Journal:  Agents Actions       Date:  1990-11

4.  Interaction of transforming growth factor-beta-1 with alpha-2-macroglobulin from normal and inflamed equine joints.

Authors:  N Coté; D R Trout; M A Hayes
Journal:  Can J Vet Res       Date:  1998-10       Impact factor: 1.310

5.  Differential effects of interleukin-1 alpha and beta on the arachidonic acid cascade in human synovial cells and chondrocytes in culture.

Authors:  I Knott; M Dieu; M Burton; V Lecomte; J Remacle; M Raes
Journal:  Agents Actions       Date:  1993-07

6.  Elevation of synovial plasminogen activator activity after injection of interleukin-1 alpha into rabbit knee joint.

Authors:  V S Ganu; R L Goldberg; V J Blancuzzi; D E Wilson; J Doughty; R Melton; E O'Byrne
Journal:  Agents Actions       Date:  1991-09

7.  Interleukin 1 induces the expression of a heat-shock gene in chondrocytes.

Authors:  T F Cruz; R A Kandel; I R Brown
Journal:  Biochem J       Date:  1991-07-15       Impact factor: 3.857

8.  Monocyte chemoattractant protein-1 (MCP-1) expression in human articular cartilage. Induction by peptide regulatory factors and differential effects of dexamethasone and retinoic acid.

Authors:  P M Villiger; R Terkeltaub; M Lotz
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

9.  A 12 year follow up study in the general population on prognostic factors of cartilage loss in osteoarthritis of the knee.

Authors:  J S Schouten; F A van den Ouweland; H A Valkenburg
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

10.  Rhein inhibits interleukin-1 beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis.

Authors:  Grégoire Martin; Patrick Bogdanowicz; Florence Domagala; Hervé Ficheux; Jean-Pierre Pujol
Journal:  Inflammation       Date:  2003-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.